Cambridge Innovation Capital Manager Ltd.

Cambridge Innovation Capital Manager Ltd.

Cambridge Innovation Capital (CIC) was established to commercialise intellectual property originating from the University of Cambridge, operating as a dedicated venture capital investor that bridges academic research and market deployment. The firm does not disclose a founding year or list named individual principals publicly; its website describes a team of investment professionals supporting portfolio companies from pre-seed to growth stage. CIC deploys capital across deep technology, life sciences, enterprise software, and climate technology, concentrating on companies with intellectual property developed at Cambridge. Its portfolio includes Oxford Nanopore Technologies, a publicly-traded DNA sequencing firm; CMR Surgical, a robotics surgery company valued above $1B; and Grid Edge, which optimises energy for commercial buildings. The firm also makes commitments to specific university spinouts and collaborates with syndicate partners on larger rounds. Its geographic focus remains the Cambridge cluster and broader East of England. CIC manages a portfolio of approximately 50 active companies. The firm does not disclose total AUM or team headcount publicly. Its investor base includes the University of Cambridge's endowment, local charitable foundations, and institutional limited partners. CIC maintains no separate philanthropic vehicle or operating business that is separately reported. The firm differentiates itself through its exclusive access to University of Cambridge spinouts, structured via a formal relationship with Cambridge Enterprise, the university's technology transfer arm. This sourcing model allows CIC to invest earlier than most venture firms, often at the proof-of-concept or seed stage, with a mandate to retain equity through to public listing or trade sale. Its governance is tied to the university's innovation strategy, creating a mission-aligned mandate focused on regional economic development.